Publications & Presentations

Scientific publications and presentations reflect the quality of the innovative research being done by our scientists and clinical collaborators.

TriSalus Clinical Essentials™

Watch this highlight from our publications and presentations.

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

Tags: Retrospective Study, Drug Delivery, Embolization

4:26 min

Share video

Browse Publications & Presentations

  • Jun 2024
  • American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract No. 2622: PERIO-02: Phase 1b Pressure Enabled Regional Immuno-oncology Trial of nelitolimod (SD-101), a Class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Abstract

Sunyoung Lee , Khaldoun Almhanna, Rahul Sheth, Shubham Pant, Joshua D. Kuban, Aaron Maxwell, Brian J. Witt, Jason LaPorte, Prajna Guha, Ann-Marie Hulstine, Bryan Cox, Richard Carvajal, Ruth White, Joshua Weintraub , Lindsey Davis, James Hart, Robert Knight, Steven C. Katz and Milind Javle
Tags: Clinical Trial, Liver Tumors
  • Mar 2024
  • Society of Interventional Radiology (SIR)

Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.

Abstract

Koustav Pal, Sanjay Gupta, Steven C. Katz & Rahul A. Sheth
Tags: Drug Delivery
  • Mar 2024
  • Society of Interventional Radiology (SIR)

The PERIO-03 Trial: Technical Feasibility and Safety of a Novel Pancreatic Retrograde Venous Immunotherapy Infusion Intervention for Locally Advanced Pancreatic Ductal Adenocarcinoma.

Abstract

Rahul A. Sheth, MD Joshua Kuban, Milan Patel, Ketan Shah, Steven C. Katz, Dan Zhao, Michael Lee
Tags: Pancreatic Tumors
  • Feb 2024
  • Current Medical Research and Opinion

Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases

Abstract

Keziah Cook, Deepshekhar Guptaa, Yunjuan Liu, Chris Miller-Rosales, Fangzhou Wei, Edward Tuttle, Steven C. Katz, Richard Marshak & Alexander Y. Kim
Tags: Liver Tumors
  • Nov 2023
  • Society for Immunotherapy of Cancer (SITC)

Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI) in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the PERIO-01 Phase 1 Trial

Presentation

Poster

Sapna P. Patel, Richard Carvajal, Kamaneh Montazeri, Jose Lutzky, Bartosz Chmielowski, Sunil Reddy, Shailander Bhatia, Shaheer Khan, Theresa Medina, Cara Haymaker, Rahul Sheth, Joshua D. Kuban, Lindsay Thornton, Eric Wehrenberg-Klee, Paula Novelli, Anthony Lucci, Vanessa Sarli, Salyna Meas, Bryan Cox, Jason LaPorte, Prajna Guha, Chandra Ghosh, Ann-Marie Hulstine, Robert Knight, Ashley Moody, David Geller, Marlana Orloff, Steven C. Katz, Diwakar DavarSapna P. Patel, Richard Carvajal, Kamaneh Montazeri, Jose Lutzky, Bartosz Chmielowski, Sunil Reddy, Shailander Bhatia, Shaheer Khan, Theresa Medina, Cara Haymaker, Rahul Sheth, Joshua D. Kuban, Lindsay Thornton, Eric Wehrenberg-Klee, Paula Novelli, Anthony Lucci, Vanessa Sarli, Salyna Meas, Bryan Cox, Jason LaPorte, Prajna Guha, Chandra Ghosh, Ann-Marie Hulstine, Robert Knight, Ashley Moody, David Geller, Marlana Orloff, Steven C. Katz, Diwakar Davar
Tags: Liver Tumors
  • Nov 2023
  • Society for Immunotherapy of Cancer (SITC)

Checkpoint Inhibitor Administered Either Systemically or Subcutaneously Enhances the Anti-Tumor Immunity of SD-101 Delivered by Pressure-Enabled Drug Delivery (PEDD™) Device in Treating Liver Metastasis (LM)

Poster

Chandra C Ghosh, PhD, Lauren Cournoyer, MD, Jennie Yujia Liu, PhD, Alizee Ballarin, BS, Prajna Guha, PhD, Bryan Cox, PhD and Steven Katz, MD
Tags: Liver Tumors
  • Nov 2023
  • Society for Immunotherapy of Cancer (SITC)

PERIO-03: Pressure-Enabled Intrapancreatic Delivery of SD-101 with Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial Safety and Feasibility Experience

Poster

Michael S. Lee, MD, Rahul Sheth, MD, Joshua D. Kuban, Ethan Ludmir, Charla McMichael, Jason LaPorte, MS, Lindsay Laudal, Ann-Marie Hulstine, Steven Katz, MD and Shubham Pant, MD
Tags: Pancreatic Tumors
  • Apr 2023
  • American Association for Cancer Research (AACR)

PERIO-01: Initial Safety Experience and Immunologic Effects of a Class C TLR9 Agonist Using Pressure-Enabled Drug Delivery (PEDD™) in a Phase 1 Trial of Hepatic Arterial Infusion of SD-101 +/- Checkpoint Inhibition in Metastatic Uveal Melanoma

Sapna P. Patel , Cara Haymaker, Rahul A. Sheth, Joshua D. Kuban, Joshua Weintraub, Eric Wehrenberg-Klee, Paula Novelli, Carin Gonsalves, Robert Adamo, Virginia Honaker, Laura Timciuc, Tarin Hennegan, Juan C. Amador-Molina, Dzifa Duose, Edwin R. Parra, Anthony Lucci, Salyna Meas, Vanessa Sarli, Victor G. Prieto, Jason LaPorte, Ann-Marie Hulstine, Ashley Moody, Bryan Cox, David Geller, Diwakar Davar, Kamaneh Montazeri, Marlana Orloff, Steven C. Katz, Richard Carvajal
Tags: Liver Tumors
  • Apr 2023
  • American Association for Cancer Research (AACR)

Enhanced Delivery of Anti PD-1 Antibody to Liver Tumors in Oncopig Using Pressure-Enabled Drug Delivery (PEDD™) Versus Systemic Delivery

David Jaroch, PhD; Chandra Ghosh, PhD; Prajna Guha, PhD; Steven C. Katz, MD; Bryan Cox, PhD; Thomas Hullinger, PhD TriSalus Life Sciences Inc., Department of Surgery, Brown University School of Medicine
Tags: Liver Tumors
  • Mar 2023
  • Journal of Vascular and Interventional Radiology – Abstract 250

Pancreatic Venous Anatomy for Trans-Portal Treatment of Pancreatic Cancers using Pressure-Enabled Drug Delivery (PEDD™)

M. Kwong, H. Spears, J. Pattee, E. Worley, G. McLennan
Tags: Pancreatic Tumors
  • Mar 2023
  • Society of Interventional Radiology (SIR) – (Late Breaking)

The Effects of a Pressure-Enabled Drug Delivery (PEDD™) Microcatheter on Radiotracer Distribution Compared to a Standard Microcatheter in Radioembolization, an Interim Analysis

P. Sutphin, E. Wehrenberg-Klee, S. Kalva, R. Uppot, V. Wu
Tags: Liver Tumors
  • Mar 2023
  • Journal of Vascular and Interventional Radiology – Abstract 140

Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure-Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors with authors.

R. Sheth, et al
Tags: Liver Tumors
  • Mar 2023
  • Society of Interventional Radiology (SIR) – Abstract 245

Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.

David B Jaroch, David J Porter, Dennis Griffin, Steven Katz, Bryan Cox
Tags: Pancreatic Tumors
  • Mar 2023
  • Society for Immunotherapy of Cancer (SITC)

Pressure-Enabled Intravascular Delivery (PEDD™) of SD-101 Into the Liver with Systemic or Subcutaneous Checkpoint Inhibitor for Control of Liver Metastases in a Murine Model

Chandra C. Ghosh, Lauren Cournoyer, Jennie Liu, Alizee Ballarin, Jason LaPorte, Prajna Guha, Bryan F. Cox, Steven C. Katz
Tags: Liver Tumors
  • Jan 2023
  • ASCO-GI

Pressure-Enabled Drug Delivery (PEDD™) of a Class C TLR9 Agonist in Combination with Checkpoint Inhibitor Therapy in a Murine Pancreatic Cancer Model

Jayanth S Shankara Narayanan, Diego A Vicente, Benedict A Capacio, Yujia Liu, Jason P LaPorte, Bryan F Cox, David B Jaroch, Steven C Katz, Rebekah R White
Tags: Pancreatic Tumors, Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Jan 2023
  • Society of Interventional Oncology (SIO)

Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD™) Versus a Standard Endhole Catheter

Thomas Hullinger, PhD, Dennis Griffin, MD, David Porter, MD, James Luethke, MD, Steven Katz, MD, Bryan Cox, PhD, David Jaroch, PhD
Tags: Liver Tumors, Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Jun 2022
  • Journal of Interventional Radiology – Abstract 333

Improved Delivery of a TLR-9 Agonist to Liver Tissue by Intravascular Pressure-Enabled Drug Delivery (PEDD™) Compared with Direct Needle Injection

D. Jaroch, et al
Tags: Liver Tumors
  • Jun 2022
  • Cancer Gene Therapy

Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition

Chandra C. Ghosh, Kara R. Heatherton, Kyle P. O’Connell, Ian S. Alexander, Deborah A. Greer, Jason LaPorte, Prajna Guha, Bryan F. Cox and Steven C. Katz
Tags: Liver Tumors, Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Jun 2022
  • Journal of Interventional Radiology – Abstract 400

Comparison of Pancreatic Tissue Uptake of Oxaliplatin Delivered by Systemic Circulation and by Pancreatic Retrograde Venous Infusion (PRVI)

D. Jaroch, J. Guo, J. LaPorte, R. Parise, D. Griffin, B. Cox, J. Beumer, A. Arepally, S. Katz
Tags: Pancreatic Tumors
  • Apr 2022
  • Society for Immunotherapy of Cancer (SITC)

Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers

Sapna P. Patel, Steven C. Katz, Rahul A. Sheth, Ravi Murthy, Virginia Honaker, Chantell M. Farinas, Mara L. Casteneda, Laura Timciuc, Tarin Hennegan, Cara Haymaker, Victor G. Prieto, Bryan Cox, Ann-Marie Hulstine, Jason LaPorte, Ashley Moody, Marlana Orloff and Richard D. Carvajal
Tags: Clinical Trial, Liver Tumors, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Nov 2021
  • Diagnostic and Interventional Radiology

Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres

Philippe d’Abadie, Stephan Walrand, Pierre Goffette, Nadia Amini, Aline van Maanen, Renaud Lhommel and François Jamar
Tags: Drug Delivery, Embolization, Liver Tumors, Retrospective Study
  • Apr 2021
  • Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion​

Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion

Chandra C. Ghosh, Kara Heatherton, Kyle O’Connell, Jason LaPorte, Prajna Guha, Bryan F. Cox, David Jaroch and Steven C. Katz
Tags: Immunomodulation, Liver Tumors, Pre-clinical Trial, TLR9 Agonist
  • Aug 2020
  • Journal for Immunotherapy of Cancer

HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure-Enabled Drug Delivery (PEDD™)

Steven C. Katz, Ashley E. Moody, Prajna Guha, John C. Hardaway, Ethan Prince, Jason LaPorte, Mirela Stancu, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Abdul Saied, Vincent Armenio and Richard P. Junghans
Tags: CAR-T, Case Report, Liver Tumors, Pressure-Enabled Regional Immunotherapy
  • Jun 2019
  • American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract No. 9555: Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

A. Amin, G.V. Long, M. Milhem, C.J. Hoimes, T. Medina, R. M. Conry, C. Lao, G. Daniels, S. Reddy, R. H. I. Andtbacka, M. Barve, M. Shaheen, T. Tüting, M. Chisamore, E. Schmidt, B. Xing, C. Guiducci, C. Obiozor, T. Bagulho, E. Gamelin, R. Janssen and A. Ribas
Tags: Clinical Trial, Immunomodulation, Liver Tumors, TLR9 Agonist
  • Jan 2019
  • Oncogene

STAT3 Inhibition Induces Bax-dependent Apoptosis in Liver Tumor Myeloid-Derived Suppressor Cells

Prajna Guha, Jillian Gardell, Josephine Darpolor, Marissa Cunetta, Matthew Lima, George Miller, N. Joseph Espat, Richard P. Junghans and Steven C. Katz
Tags: Immunomodulation, Liver Tumors, Pre-clinical Study, TLR9 Agonist
  • Jan 2019
  • Cardiovascular and Interventional Radiology

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

Joseph J. Titano, Aaron M. Fischman, Arnav Cherian, Madeline Tully, Lance L. Stein, Louis Jacobs, Raymond A. Rubin, Michael Bosley, Steve Citron, Dean W. Joelson, Roshan Shrestha and Aravind Arepally
Tags: Drug Delivery, Embolization, Liver Tumors, Retrospective Study
  • Nov 2018
  • Society for Immunotherapy of Cancer (SITC)

HITM-SURE: Phase Ib CAR-T Hepatic Artery Infusion Trial for Stage IV Adenocarcinoma using Pressure-Enabled Drug Delivery Technology

Steven C. Katz, Prajna Guha, John C. Hardaway, Ethan Prince, Ashley Moody, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Jerry Zeldis, Vincent Armenio, N. Joseph Espat and Richard P. Junghans
Tags: CAR-T, Clinical Trial, Drug Delivery, Liver Tumors
  • Apr 2018
  • Journal of Vascular and Interventional Radiology

Abstract No. 133: Surefire Infusion System (SIS) Hepatocellular Carcinoma Registry Study Interim Results: a Multicenter Study of the Safety, Feasibility, and Outcomes of the SIS Expandable-Tip Microcatheter in DEB-TACE

B. Kapoor, F. Contreras, M. Katz, A. Arepally, A. Fischman, S. Rose, A. Kim and J. Ferraro
Tags: Clinical Trial, Drug Delivery, Embolization, Liver Tumors
  • Sep 2017
  • PlOS One

Short-term Imaging Response after Drug-Eluting Embolic Trans-Arterial Chemoembolization Delivered with the Surefire Infusion System® for the Treatment of Hepatocellular Carcinoma

Alexander Y. Kim, Shelby Frantz, Pranay Krishnan, Danielle DeMulder, Theresa Caridi, George Emmett Lynskey and James B. Spies
Tags: Clinical Trial, Drug Delivery, Embolization, Liver Tumors
  • May 2015
  • Journal of Vascular and Interventional Radiology

The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study

Alexander S. Pasciak, James H. McElmurray, Austin C. Bourgeois, R. Eric Heidel and Yong C. Bradley
Tags: Drug Delivery, Embolization, Liver Tumors, Prospective Study
Load More

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL